logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
B

Beverly Moy

Harvard Medical School
H指数:57
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Actionable genetic landscape and dynamics in circulating DNA from 12,827 patients with metastatic breast cancer

来自12,827例转移性乳腺癌患者循环DNA中可操作的遗传景观和动态

Nature Communications
IF15.7
2026-09-220
OAAI
Ignaty Leshchiner; Arielle J. Medford; Justin Cha; Lesli A. Kiedrowski; Andrzej Niemierko; Jennifer C. Keenan; Charles S. Dai; Laura M. Spring; Beverly Moy; Seth A. Wander; Neelima Vidula; Steven J. Isakoff; Dejan Juric; Mendy Miller; Andrew A. Davis; Lorenzo Gerratana; Ami Shah; Ben H. Park; Adam Brufsky; Joyce O’Shaughnessy; Rebecca J. Nagy; Leif W. Ellisen; Massimo Cristofanilli; Aditya Bardia; Gad Getz
Genomic biomarkers of ipatasertib response in patients with hormone receptor-positive metastatic breast cancer

激素受体阳性转移性乳腺癌患者中ipatasertib反应的基因组生物标志物

npj Breast Cancer
IF7.6
2026-09-140
OAAI
Maxwell R. Lloyd; Zahra Bagheri; Elizabeth C. Scott; Geoffrey G. Fell; Lianne Ryan; Jennifer C. Keenan; Andrzej Niemierko; Laura M. Spring; Jennifer Shin; Steven J. Isakoff; Beverly Moy; Sarah Padden; Elizabeth Fisher; Amber Newton; Karleen R. Habin; Elene T. Viscosi-Spieler; Lauren Scarpetti; Andreas Varkaris; Leif W. Ellisen; Taronish Dubash; Dante Che; Parasvi S. Patel; Ferran Fece de la Cruz; Douglas S. Micalizzi; Shyamala Maheswaran; Daniel A. Haber; Dejan Juric; Aditya Bardia; Seth A. Wander
Safety and antitumour activity of ipatasertib combined with endocrine therapy and a CDK4/6 inhibitor in HR+/HER2– metastatic breast cancer (TAKTIC): a single-centre, open-label, phase 1b trial

伊帕西替布联合内分泌疗法和CDK4/6抑制剂在HR+/HER2–转移性乳腺癌中的安全性和抗肿瘤活性（TAKTIC）：一项单中心、开放标签、1b期临床试验

The Lancet Oncology
IF0
2026-04-270
PRE
Seth A Wander; Maxwell R Lloyd; Jennifer C Keenan; Elizabeth C Scott; Andrzej Niemierko; Laura M Spring; Geoffrey G Fell; Jennifer Shin; Steven J Isakoff; Beverly Moy; Lianne Ryan; Sarah Padden; Elizabeth Fisher; Amber Newton; Karleen R Habin; Elene T Viscosi-Spieler; Lauren Scarpetti; Andreas Varkaris; Leif W Ellisen; Taronish Dubash
Development and Refinement of a Nurse-Led, Culturally Sensitive Intervention for Adjuvant Endocrine Therapy Initiation Among Patients with Breast Cancer

针对乳腺癌患者辅助内分泌治疗启动的护士主导、文化敏感型干预措施的开发与完善

European Journal of Oncology Nursing
IF2.7
2025-10-150
PRE
Kathryn E. Post; Laura Dunderdale; Shibani Datta; Nichole Gutierrez; Leticia Varella; Nora Horick; Lara Traeger; Joseph A. Greer; Beverly Moy; Jennifer S. Temel; Jamie M. Jacobs
Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER)
NPJ BREAST CANCER
IF7.6
2025-01-070
OA
Spring, Laura M.; Scarpetti, Lauren; Medford, Arielle J.; Niemierko, Andrzej; Comander, Amy; Mulvey, Therese; Schnipper, Lowell; Isakoff, Steven J.; Moy, Beverly; Wander, Seth A.; Shin, Jennifer; Ephrem, Zanta; Laposta, Anneke R.; Denault, Elyssa; Abraham, Elizabeth; Calistro, Gayle; Kalashnikova, Ekaterina; Rodriguez, Angel; Liu, Minetta C.; Aleshin, Alexey; Peppercorn, Jeffrey; Ellisen, Leif W.; Bardia, Aditya
Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: Translational Breast Cancer Research Consortium trial 022

Neratinib和ado-曲妥珠单抗emtansine用于预处理和未治疗的人表皮生长因子受体2 (HER2) 阳性乳腺癌脑转移: 转化乳腺癌研究联盟试验022

ANNALS OF ONCOLOGY
IF65.4
2024-11-011
OAAI
Freedman, R. A.; Heiling, H. M.; Li, T.; Trapani, D.; Tayob, N.; Smith, K. L.; Davis, R.; Pereslete, A. M.; Demeo, M. K.; Cotter, C.; Chen, W. Y.; Parsons, H. A.; Santa-Maria, C. A.; Van Poznak, C.; Moy, B.; Brufsky, A. M.; Melisko, M. E.; o'Sullivan, C. C.; Ashai, N.; Rauf, Y.; Nangia, J. R.; Burns, R. T.; Savoie, J.; Wolff, A. C.; Winer, E. P.; Rimawi, M. F.; Krop, I. E.; Lin, N. U.
Enrolling a diverse sample of community health center patients for a multi-level intervention to increase colorectal cancer screening uptake and follow-up
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
IF3.4
2024-09-210
PRE
May, Folasade P.; Tuan, Jessica J.; Brodney, Suzanne; Syngal, Sapna; Chan, Andrew T.; Glenn, Beth; Johnson, Gina; Chang, Yuchiao; Drew, David A.; Moy, Beverly; Rodriguez, Nicolette J.; Warner, Erica T.; Anyane-Yeboa, Adjoa; Ukaegbu, Chinedu; Davis, Anjelica Q.; Schoolcraft, Kimberly; Kuney, Samantha; Le Beaux, Kelley; Jeffries, Catherine; Haas, Jennifer S.
Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer

抗体药物偶联物Sacituzumab Govitecan可在乳腺癌患者中实现序贯TOP1/PARP抑制剂治疗策略

CLINICAL CANCER RESEARCH
IF10.2
2024-05-066
OAAI
Bardia, Aditya; Sun, Sheng; Thimmiah, Nayana; Coates, James T.; Wu, Bogang; Abelman, Rachel O.; Spring, Laura; Moy, Beverly; Ryan, Phoebe; Melkonyan, Mark N.; Partridge, Ann; Juric, Dejan; Peppercorn, Jeffrey; Parsons, Heather; Wander, Seth A.; Attaya, Victoria; Lormil, Brenda; Shellock, Maria; Nagayama, Aiko; Bossuyt, Veerle; Isakoff, Steven J.; Tolaney, Sara M.; Ellisen, Leif W.
Functional decline in older breast cancer survivors treated with and without chemotherapy and non-cancer controls: results from the Hurria Older PatiEnts (HOPE) prospective study

接受或不接受化疗和非癌症对照的老年乳腺癌幸存者的功能下降: 来自Hurria老年患者 (HOPE) 前瞻性研究的结果

JOURNAL OF CANCER SURVIVORSHIP
IF2.9
2024-04-282
PRE
Sedrak, Mina S.; Sun, Can-Lan; Bae, Marie; Freedman, Rachel A.; Magnuson, Allison; O'Connor, Tracey; Moy, Beverly; Wildes, Tanya M.; Klepin, Heidi D.; Chapman, Andrew E.; Tew, William P.; Dotan, Efrat; Fenton, Mary Anne; Kim, Heeyoung; Katheria, Vani; Muss, Hyman B.; Cohen, Harvey J.; Gross, Cary P.; Ji, Jingran
Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial

sacituzumab govitecan治疗局部三阴性乳腺癌的新辅助治疗: 来自NeoSTAR试验的结果

ANNALS OF ONCOLOGY
IF65.4
2024-03-0113
OA
Spring, L. M.; Tolaney, S. M.; Fell, G.; Bossuyt, V.; Abelman, R. O.; Wu, B.; Maheswaran, S.; Trippa, L.; Comander, A.; Mulvey, T.; McLaughlin, S.; Ryan, P.; Ryan, L.; Abraham, E.; Rosenstock, A.; Garrido-Castro, A. C.; Lynce, F.; Moy, B.; Isakoff, S. J.; Tung, N.; Mittendorf, E. A.; Ellisen, L. W.; Bardia, A.
Intratumoral heterogeneity drives resistance to Antibody Drug Conjugate therapy: Analysis of the NeoSTAR trial of neoadjuvant Sacituzumab govitecan for localized TNBC
CANCER RESEARCH
IF16.6
2024-02-010
PRE
Spring, Laura M.; Wu, Bogang; Liu, Ting; Geisberg, Jacob; Cristea, Simona; Bossuyt, Veerle; Abelman, Rachel Occhiogrosso; Peiris, Nicole; Coates, James; Koh, Siang-Boon; Zhang, Mengran; Ryan, Lianne; Moy, Beverly; Isakoff, Steven J.; Tolaney, Sara M.; Michor, Franziska; Bardia, Aditya; Ellisen, Leif W.
Falls prechemotherapy and toxicity-related hospitalization during adjuvant chemotherapy for breast cancer in older women: Results from the prospective multicenter HOPE trial
CANCER
IF5.1
2023-11-142
OAAI
Ji, Jingran; Bae, Marie; Sun, Can-Lan; Wildes, Tanya M.; Freedman, Rachel A.; Magnuson, Allison; O'Connor, Tracey; Moy, Beverly; Klepin, Heidi D.; Chapman, Andrew E.; Tew, William P.; Dotan, Efrat; Fenton, Mary Anne; Kim, Heeyoung; Katheria, Vani; Gross, Cary P.; Cohen, Harvey J.; Muss, Hyman B.; Sedrak, Mina S.

研究方向

暂未获取到该数据
A
Aditya Bardia
H 指数:86论文数:1,148被引数:3.8万
L
Laura M. Spring
H 指数:36论文数:469被引数:6,831
S
Steven J. Isakoff
H 指数:60论文数:449被引数:2.6万
L
Leif W. Ellisen
H 指数:66论文数:464被引数:2.4万
D
Dejan Juric
H 指数:59论文数:732被引数:2.0万
S
Seth A. Wander
H 指数:35论文数:342被引数:5,365
N
Neelima Vidula
H 指数:22论文数:171被引数:1,353
A
Antonio C. Wolff
H 指数:99论文数:905被引数:5.8万
A
Andrzej Niemierko
H 指数:69论文数:483被引数:1.7万
N
Nancy U. Lin
H 指数:95论文数:1,074被引数:4.2万